2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Non-Hodgkin
37
Lymphoma
37
Lymphoma, Follicular
33
Lymphoma, Large B-Cell, Diffuse
30
Lymphoma, Mantle-Cell
22
Lymphoma, B-Cell, Marginal Zone
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Waldenstrom Macroglobulinemia
9
Lymphoma, Large-Cell, Immunoblastic
9
Burkitt Lymphoma
9
Lymphoma, B-Cell
6
Lymphoma, Large-Cell, Anaplastic
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Leukemia
2
Recurrence
1
Orbital lymphoma
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, AIDS-Related
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oncology Patients Receiving Chemotherapy
×
ibritumomab tiuxetan
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts